
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical Ltd has achieved a significant operational milestone by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, enabling the company to commence U.S. manufacturing of its Alpha DaRT technology by 2026. The strong cash position of the company supports its ongoing developments, which position it favorably to address unmet needs in the oncology sector. Despite a reported net loss of $11.7 million, which is higher than prior estimates, the development advances and potential therapeutic applications of Alpha DaRT contribute to a positive future outlook for the company.
Bears say
Alpha Tau Medical Ltd reported a net loss of $11.7 million in the third quarter of 2025, highlighting financial challenges as the company advances its clinical-stage oncology therapeutics. The company faces significant risks related to the potential failure of its AlphaDaRT technology in clinical trials, the inability to secure regulatory approval in the U.S., and challenges in achieving market success, including competition and market size limitations. Additionally, concerns regarding potential dilution further exacerbate the negative outlook on the stock, indicating substantial uncertainties in the company's future financial performance.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares